| |
 |
|
Class Information
Number: 424/234.1
Name: Drug, bio-affecting and body treating compositions > Antigen, epitope, or other immunospecific immunoeffector (e.g., immunospecific vaccine, immunospecific stimulator of cell-mediated immunity, immunospecific tolerogen, immunospecific immunosuppressor, etc.) > Bacterium or component thereof or substance produced by said bacterium (e.g., legionella, borrelia, anaplasma, shigella, etc.)
Description: Subject matter involving a bacterium, a component of a bacterium, or a substance produced by a bacterium.
Sub-classes under this class:
| Class Number |
Class Name |
Patents |
| 424/246.1 |
Bacillus |
69 |
| 424/253.1 |
Bordetella (e.g., bordetella bronchiseptica, etc.) |
69 |
| 424/252.1 |
Brucella (e.g., brucella abortus, brucella canis, etc.) |
31 |
| 424/263.1 |
Chlamydia (e.g., chlamydia trachomatis, etc.) |
78 |
| 424/247.1 |
Clostridium (e.g., clostridium tetani, clostridium difficile, clostridium perfringens, clostridium botulinum, clostridium chauvoei, etc.) |
98 |
| 424/245.1 |
Corynebacterium (e.g., corynebacterium diphtheriae, etc.) |
47 |
| 424/257.1 |
Escherichia (e.g., escherichia coli, etc.) |
150 |
| 424/256.1 |
Hemophilus (e.g., hemophilus influenzae, hemophilus gallinarum, hemophilus pleuropnemoniae, etc.) |
196 |
| 424/259.1 |
Klebsiella (e.g., klebsiella pneumoniae, etc.) |
30 |
| 424/251.1 |
Moraxella (e.g., moraxella bovis, etc.) |
55 |
| 424/248.1 |
Mycobacterium (e.g., mycobacterium tuberculosis, calmette-guerin bacillus (i.e., bcg), etc.) |
233 |
| 424/264.1 |
Mycoplasma |
46 |
| 424/249.1 |
Neisseria (e.g., neisseria gonorrhoeae, etc.) |
93 |
| 424/255.1 |
Pasteurella (e.g., pasteurella multocida, pasteurella hemolytica, etc.) |
88 |
| 424/242.1 |
Pilus, fimbria, or adhesin |
81 |
| 424/260.1 |
Pseudomonas (e.g., pseudomonas aeruginosa, etc.) |
90 |
| 424/258.1 |
Salmonella (e.g., salmonella typhimurium, etc.) |
142 |
| 424/243.1 |
Staphylococcus (e.g., staphylococcus aureus, etc.) |
107 |
| 424/244.1 |
Streptococcus (e.g., group b streptococcus, pneumococcus or streptococcus pneumoniae, etc.) |
300 |
| 424/236.1 |
Toxin or toxoid, except endotoxin (e.g., exotoxin, enterotoxin, etc.) |
329 |
| 424/235.1 |
Transposon mutant or deletion mutant bacterium (e.g., produced by transposon mutagenesis, etc.) |
94 |
| 424/262.1 |
Treponema (e.g., treponema hyodysenteriae, treponema pallidum, etc.) |
42 |
| 424/261.1 |
Vibrio (e.g., vibrio cholera, etc.) |
82 |
Patents under this class:
| Patent Number |
Title Of Patent |
Date Issued |
| 5968548 |
Use of liposome encapsulated cirprofloxacin as an immunotherapeutic drug |
Oct. 19, 1999 |
| 5961983 |
Stable pura vectors and uses therefor |
Oct. 5, 1999 |
| 5955077 |
Tuberculosis vaccine |
Sep. 21, 1999 |
| 5955078 |
Fibronectin binding protein polypeptides |
Sep. 21, 1999 |
| 5955090 |
Immunogenic hybrid protein OprF-OprI derived from Pseudomonas aeruginosa membrane proteins |
Sep. 21, 1999 |
| 5951987 |
Polysaccharide vaccine to enhance immunity against brucellosis |
Sep. 14, 1999 |
| 5951988 |
Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods |
Sep. 14, 1999 |
| 5942236 |
Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines |
Aug. 24, 1999 |
| 5942237 |
Pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane |
Aug. 24, 1999 |
| 5939075 |
Mutants of Brucella melitensis |
Aug. 17, 1999 |
| 5935580 |
Recombinant mutants for inducing specific immune responses |
Aug. 10, 1999 |
| 5932217 |
Peptides which inhibit adhesion between leukocytes and endothelial cells |
Aug. 3, 1999 |
| 5932220 |
Diagnostic tests for a new spirochete, Borrelia lonestari sp. nov. |
Aug. 3, 1999 |
| 5928644 |
T-cell epitopes |
Jul. 27, 1999 |
| 5928647 |
Inducing cytotoxic T lymphocyte responses |
Jul. 27, 1999 |
| 5928879 |
Method of diagnosing human granulocytic Ehrlichiosis |
Jul. 27, 1999 |
| 5929109 |
Enhancing and stabilizing agent of the activity of Bifidus factor |
Jul. 27, 1999 |
| 5925354 |
Riboflavin mutants as vaccines against Actinobacillus pleuropneumoniae |
Jul. 20, 1999 |
| 5925361 |
Ornithobacterium rhinotracheale vaccines |
Jul. 20, 1999 |
| 5922323 |
Transferrin receptor genes and immunogenic compositions derived therefrom |
Jul. 13, 1999 |
| 5922845 |
Therapeutic multispecific compounds comprised of anti-Fc.alpha. receptor antibodies |
Jul. 13, 1999 |
| 5922848 |
Method of recovering shiga-like toxins and vaccines comprising inactivated shiga-like toxin |
Jul. 13, 1999 |
| 5919463 |
Clostridium difficle toxins as mucosal adjuvants |
Jul. 6, 1999 |
| 5919640 |
Streptococcus suis adhesin protein and method for producing it |
Jul. 6, 1999 |
| 5916571 |
Immunostimulating activity of streptococcus pneumoniae serotype 8 oligosaccharides |
Jun. 29, 1999 |
| 5914114 |
Method of raising antibodies against E. coli of the family CS4-CFA/I |
Jun. 22, 1999 |
| 5912323 |
Zonula occludens toxin receptors |
Jun. 15, 1999 |
| 5910306 |
Transdermal delivery system for antigen |
Jun. 8, 1999 |
| 5908630 |
Swine immunization using live, RTX toxin-secreting organisms |
Jun. 1, 1999 |
| 5906826 |
Method of inducing an immune response in a young animal |
May. 25, 1999 |
| 5895653 |
Adjuvant based on colloidal iron compounds |
Apr. 20, 1999 |
| 5891438 |
Method for stimulating production of variable region gene family restricted antibodies through B-cell superantigen vaccination |
Apr. 6, 1999 |
| 5891443 |
Method to produce granulocyte colony stimulating factor from immortalized avian T lymphocytes to produce immortalized cells |
Apr. 6, 1999 |
| 5888519 |
Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections |
Mar. 30, 1999 |
| 5885587 |
Efficacious vaccines against Bordetella pertussis comprising a combination of individually purified pertussis antigens |
Mar. 23, 1999 |
| 5885823 |
Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents |
Mar. 23, 1999 |
| 5879683 |
Antibacterial agent containing tea extract or active fraction thereof and .beta.-lactam antibiotic |
Mar. 9, 1999 |
| 5879952 |
43 Kd protein vaccine and method for the production thereof |
Mar. 9, 1999 |
| 5876725 |
Actinobacillus pleuropneumoniae transferrin binding protein vaccines and uses thereof |
Mar. 2, 1999 |
| 5876966 |
Compounds and methods for the stimulation and enhancement of protective immune responses and IL-12 production |
Mar. 2, 1999 |
| 5871749 |
Therapeutic treatment of H. pylori associated gastroduodenal disease |
Feb. 16, 1999 |
| 5871751 |
Renibacterium salmoninarum vaccine and method for its preparation |
Feb. 16, 1999 |
| 5869064 |
Protein rib, a cell surface protein that confers immunity to many strains of the group B Streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition |
Feb. 9, 1999 |
| 5866132 |
Immunogenic oligosaccharide compositions |
Feb. 2, 1999 |
| 5866134 |
Method for enhancing the antibody response to specific antigens with Interleukin-10 |
Feb. 2, 1999 |
| 5866140 |
Type I surface antigen associated with staphylococcus epidermidis |
Feb. 2, 1999 |
| 5863541 |
AAV capsid vehicles for molecular transfer |
Jan. 26, 1999 |
| 5864014 |
Zonula occludens toxin receptor |
Jan. 26, 1999 |
| 5861162 |
Multivalent inocula for lessening incidence of liver abscesses in cattle |
Jan. 19, 1999 |
| 5861163 |
Process for preparing a vaccine against pseudomonas aeruginosa using attenuated strains |
Jan. 19, 1999 |
|
|
|
